Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases

BACKGROUND AND OBJECTIVESThe aim of this project is to assess diagnostic reclassification based on molecular data over morphology in a series of glial tumours since the introduction of the 2016 WHO classification of brain tumours. MATERIALS AND METHODSRetrospective review of glial tumours (oligodend...

Full description

Saved in:
Bibliographic Details
Published in:Neurocirugía (Barcelona. Internet. English ed.) 2019-01, Vol.30 (1), p.19-27
Main Authors: Valera-Melé, Marc, Mateo Sierra, Olga, Sola Vendrell, Emma, Guzmán de Villoria L, Juan Adán, Carvajal Díaz, Lorena, Gil de Sagredo Del Corral, Óscar Lucas, García Leal, Roberto
Format: Article
Language:eng ; spa
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND AND OBJECTIVESThe aim of this project is to assess diagnostic reclassification based on molecular data over morphology in a series of glial tumours since the introduction of the 2016 WHO classification of brain tumours. MATERIALS AND METHODSRetrospective review of glial tumours (oligodendrogliomas and astrocytomas) treated in our centre between January 2012 and June 2016 in which a review of diagnosis was performed when molecular studies were added. Statistical analysis included evaluation of variables of epidemiology, morphology and molecular data (mainly IDH mutation and 1p19q codeletion), diagnostic changes after new classification was considered, and clinical impact in cases of diagnostic reclassification. RESULTSFrom a total of 147 glial tumours reviewed in our centre, molecular diagnosis was obtained in 74 cases (50.3%). Initial diagnosis changed in 23 cases (31%), and 20 (87%) of them had a prior histological diagnosis of oligodendroglioma (69.6% grade ii and 17.4% grade iii). Only 3 of these 23 cases diagnosis changed from astrocytoma to oligodendroglioma. Among reclassified tumours, there was a common molecular pattern, as findings showed mutant IDH in 16 cases (69.6%) and no codeletion in 20 cases (87%). According to the cell of origin, of the whole group of 27 oligodendrogliomas in our series (reclassified and non-reclassifed), 20 cases (74%) became astrocytomas, despite typical oligodendroglial morphology, due to absence of 1p19q codeletion. There was a trend for diagnosis reclassification in younger patients (
ISSN:2529-8496
DOI:10.1016/j.neucir.2018.09.002